Plasma interleukin-8 levels in patients with post-hepatitic cirrhosis: Relationship to severity of liver disease, portal hypertension and hyperdynamic circulation

Journal of Gastroenterology and Hepatology (Australia)

Volumn 11, Issue 7, 1996, Pages 635-640

  Li, Chung Pin ^a   Lee, Fa Yauh ^a,b   Tsai, Yang Te ^a   Lin, Han Chieh ^a   Lu, Rei Hwa ^a   Hou, Ming Chih ^a   Wang, Teh Fang ^a   Chen, Ling Sheng ^a   Wang, Sun Sang ^a   Lee, Shou Dong ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

cirrhosis; interleukin 8; portal hypertension; post hepatitic

Indexed keywords

INTERLEUKIN 8;

ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; HEPATITIS; HUMAN; LIVER BLOOD FLOW; LIVER CIRRHOSIS; LIVER VEIN; MAJOR CLINICAL STUDY; MALE; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; SYSTEMIC VASCULAR RESISTANCE; VENOUS PRESSURE;

EID: 0029833659     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1996.tb00306.x     Document Type: Article

References (40)

1. Lindley I, Aschauer H, Seifert JM et al. Synthesis and expression in Escherichia coli of the gene encoding monocyte-derived neutrophil-activating factor: Biological equivalence between natural and recombinant neutrophil-activating factor. Proc. Natl Acad. Sci. USA 1988; 85: 9199-203.
2. Baggiolini M, Walz A, Kunkel SL. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J. Clin Invest. 1989; 84: 1045-9.
3. Westwick J, Li SW, Camp RD. Novel neutrophil-stimulating peptides. Immunol. Today 1989; 10: 146-7.
4. Matsushima K, Morishita K, Yoshimura T et al. Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor. J. Exp. Med. 1988; 167: 1883-93.
5. Stricter RM, Kunkel SL, Showell HJ et al. Endothelial cell gene expression of a neutrophil chemotactic factor by TNF-α, LPS, and IL-1β. Science 1989; 243: 1467-9.
6. Mielke V, Bauman JGJ, Sticherling M et al. Detection of neutrophil-activating peptide NAP/IL-8 and NAP IL-8 mRNA in human recombinant IL-1α- and human recom-binant tumor necrosis factor-α-stimulated human dermal fibroblasts. An immunocytochemical and fluorescent in situ hybridization study. J. Immunol. 1990; 144: 153-61.
7. Thornton AJ, Strieter RM, Lindley I, Baggiolini M, Kunkel SL. Cytokine-induced gene expression of a neutrophil chemotactic factor/IL-8 in human hepatocytes. J. Immunol. 1990; 144: 2609-13.
8. Van Zee KJ, DeForge LE, Fischer F et al. IL-8 in septic shock, endotoxemia, and after II-1 administration. J. Immunol. 1991; 146: 3478-82.
9. DeForge LE, Remick DG. Kinetics of TNF, IL-6, and IL-8 gene expression in LPS-stimulated human whole blood. Biochem. Biophys. Res. Commun. 1991; 174: 18-24.
10. Standiford TJ, Kunkel SL, Basha MA et al. Interleukin-8 gene expression by a pulmonary epithelial cell line: A model for cytokine networks in the lung. J. Clin. Invest. 1990; 86: 1945-53.
11. Van Deventer SJH, Hart M, Van der Poll T, Hack CE, Aarden LA. Endotoxin and tumor necrosis factor-alpha-induced interleukin-8 release in humans. J. Infect. Dis. 1993; 167: 461-4.
12. Stricter RM, Kasahara K, Allen RM et al. Cytokine-induced neutrophil-derived interleukin-8. Am. J. Pathol. 1992; 141: 397-407.
13. Danner RL, Suffredini AF, Van Derrort AL et al. Detection of interleukin 6 (IL-6) and interleukin 8 (IL-8) during septic shock in humans. Clin. Res. 1990; 38: 352a (Abstract).
14. Redl H, Schlag G, Bahrami S, Schade U, Ceska M, Stütz P. Plasma neutrophil-activating peptide-1 interleukin-8 and neutrophil elastase in a primate bacteremia model. J. Infect. Dis. 1991; 164: 383-8.
15. Al-Wabel A, Al-Knawy B, Raziuddin S. Interleukin-8 and granulocyte-macrophage colony-stimulating factor secretion in hepatocellular carcinoma and viral chronic active hepatitis. Clin. Immunol. Immunopathol. 1995; 74: 231-5.
16. Sheron N, Bird G, Koskinas J et al. Circulating and tissue levels of the neutrophil chemotaxin interleukin-8 are elevated in severe acute alcoholic hepatitis, and tissue levels correlate with neutrophil infiltration. Hepatology 1993; 18: 41-6.
17. Curtiss SI, Eickmever D, Faire B et al. Cytokine levels correlate with disease severity in patients with end-stage liver disease. Hepatoloy 1994; 20: 191A (Abstract).
18. Genecin P, Groszmann RJ. Portal hypertension. In: Schiff F., Schiff L, eds. Diseases of the Liver, 7th edn. Philadelphia: Lippincott, 1993; 935-73.
19. Suffredini AF, Fromm RE, Parker MM et al. The cardiovascular response of normal humans to the administration of endotoxin. N. Engl. J. Med. 1989; 321: 280-7.
20. Parker MM, Parrillo JE. Septic shock. Hemodynamics and pathogenesis. JAMA 1983; 250: 3324-7.
21. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: A role for nitric oxide? Lancet 1991; 337: 776-8.
22. Michie HR, Manogue KR, Spriggs DR et al. Detection of circulating tumor necrosis factor after endotoxin administration. N. Engl. J. Med. 1988; 318: 1481-6.
23. Starnes HF Jr, Pearce MK, Tewari A, Yim JH, Zou JC, Abrams JS. Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-u challenge in mice. J. Immunol. 1990; 145: 4185-91.
24. Harbrecht BG, Di Silvio M, Demetris AJ, Simmons RL, Billiar TR. Tumor necrosis factor-α regulates in vivo nitric oxide synthesis and induces liver injury during endotoxemia. Hepatology 1994; 20: 1055-60.
25. Scott-Burden T, Schini VB, Vanhoutte PM. Induction by inerleukin-1 of nitric oxide synthase leads to inhibition of mitogen-stimulated DNA synthesis in cultured vascular smooth muscle cells. In: Moncada S, Marletta MA, Hibbs JB Jr, Higgs EA, eds. The Biology of Nitric Oxide. I. Physiological and Clinical Aspects. London: Portland Press, 1992; 48-52.
26. Wang X, Han CD, Fiscus RR, Qi M, Jones SB. Hypotension- and endotoxin-induced alterations in calcitonin gene-related peptide: Modulation by dexamethasone. Circ. Shock 1991; 34: 217-23.
27. Lopez-Talavera JC, Merrill WW, Groszmann RJ. Tumor necrosis factor α: A major contributor to the hyperdynamic circulation in prehepatic portalhypertensive rats. Gastroenterology 1995; 108: 761-7.
28. Lee FY, Lu RH, Tsai YT et al. Circulating tumor necrosis factor-α and interleukin-6 concentrations and hyperdynamic circulation in cirrhosis. Hepatology 1995; 22: 256A Abstract).
29. Van Zee KJ, Fischer E, Hawes AS et al. Effects of intravenous IL-8 administration in nonhuman primates. J. Immunol. 1992; 148: 1746-52.
30. Baggiolini M, Imboden P, Detmers P. Neutrophil activation and the effects of interleukin-8 neutrophil-activating peptide 1 (IL-8/NAP-1). In: Baggiolini M, Sorg C, eds. Interleukin 8 (NAP-1) and Related Chemotactic Cytokines. Cytokines, vol 4. Basel: Karger, 1992; 1-17.
31. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the esophagus for bleeding esophageal varices. Br. J. Surg. 1973; 60: 646-9.
32. Lin RS, Lee FY, Lee SD et al. Endotoxemia in patients with chronic liver diseases: Relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J. Hepatol. 1995; 22: 165-72.
33. Tsai YT, Lee FY, Lin HC et al. Lack of effects of isosorbide-5-mononitrate on hepatic hemodynamics in HBsAg-positive cirrhosis. Hepatology 1989; 10: 283-7.
34. Taub DD, Oppenheim JJ. Review of the Chemokine meeting, the Third International Symposium of Chemotactic Cytokines. Cytokine 1993; 5: 175-9.
35. Matsushima K, Baldwin ET, Mukaida N. Interleukin-8 and MCAF: Novel leukocyte recruitment and activating cytokines. Chem. Immunol. 1992; 51: 236-65.
36. Castell JV, Geiger T et al. Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat. Eur. J. Bioehem. 1988; 177: 357-61.
37. Klapproth J, Castell J, Geiger T, Andus T, Heinrich PC. Fate and biological action of human recombinant interleukin I beta in the rat in vivo. Eur. J. Immunol. 1989; 19: 1485-90.
38. Sonne O, Davidsen O, Möller BK, Munck Petersen C. Cellular targets and receptors for interleukin-6. I. In vivo and in vitro uptake of IL-6 in liver and hepatocytes. Eur. J. Clin. Invest. 1990; 20: 366-76.
39. Ferraiolo BL, Moore JA, Crase D, Gribling P, Wilking H, Baughman RA. Pharmacokinetics and tissue distribution of recombinant human tumor necrosis factor-α in mice. Drug Metab. Dispos. 1988; 16: 270-5.
40. Larsen CG, Anderson AO, Appella E, Oppenheim JJ, Matsushima K. The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes. Science 1989; 243: 1464-7.